TY - CHAP M1 - Book, Section TI - Hypercholesterolemia, Hyperlipoprotein(a), Hypertriglyceridemia, and Low HDL A1 - Rosenson, Robert S. A1 - Koschinsky, Marlys L. A1 - Nordestgaard, Børge G. A1 - Hegele, Robert A. A2 - Fuster, Valentin A2 - Narula, Jagat A2 - Vaishnava, Prashant A2 - Leon, Martin B. A2 - Callans, David J. A2 - Rumsfeld, John S. A2 - Poppas, Athena PY - 2022 T2 - Fuster and Hurst's The Heart, 15e AB - Content UpdateSafety and Pharmacodynamic Effects of VERVE-101, an Investigational DNA Base Editing Medicine Designed to Durably Inactivate the PCSK9 Gene and Lower LDL Cholesterol - Interim Results of the Phase 1b Heart-1 TrialThe Heart-1 trial was a phase 1b, open-label clinical trial designed to assess the safety and pharmacodynamic effects of an investigational CRISPR-based gene editing therapy that inactivates the PCSK9 gene in the liver. Read More SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accesscardiology.mhmedical.com/content.aspx?aid=1205976850 ER -